Teva Recalls Blood Pressure Drug Over Elevated Cancer-Linked Impurity

Teva Pharmaceuticals USA has issued a nationwide recall of hundreds of thousands of bottles of a commonly prescribed blood pressure medication after internal testing detected elevated levels of a chemical impurity linked to cancer risk, prompting renewed attention on drug manufacturing oversight and patient safety. The voluntary recall involves more than 580,000 bottles of prazosin hydrochloride capsules in 1 mg, 2 mg, and 5 mg strengths. Teva initiated the recall on October 7, 2025, after identifying higher-than-acceptable levels of N-nitroso prazosin impurity C, a nitrosamine classified as a probable human carcinogen. The U.S. Food and Drug Administration formally designated the action as a Class II recall on October 24, meaning use of the affected product may cause temporary or medically reversible health effects, with only a remote chance of serious harm. The recalled medication was distributed nationwide under Teva’s label, including through partners such as Amerisource Health S...